Kevin Strang
Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
About Kevin Strang
Kevin Strang is recorded as Analyst at Goldman Sachs. Kevin Strang has spoken on 3 earnings calls and 3 other investor events across 3 companies, most recently for Stoke Therapeutics, Inc. on October 29, 2026. Those appearances were for Praxis Precision Medicines, Inc. (PRAX), Stoke Therapeutics, Inc. (STOK) and Xenon Pharmaceuticals Inc. (XENE). The companies whose calls Kevin Strang spoke on are classified in the Healthcare sector.
Kevin Strang on recent calls
“Just a question on the design for Emperor in terms of data quality monitoring. Can you walk us through, you know, how you designed the trial with that in mind in terms of the Violent 3 subdomains cores, how you could consistently collect that across different time points, across different sites?”
“One question on XTOL3, just as this is enrolling, and I think you've mentioned this is expanded to include Japanese patients. I guess, what are you seeing in terms of baseline characteristics, or what are you expecting in terms of baseline characteristics?”
“You alluded to the design being more important versus the drug itself. Do you mind walking us through sort of some of the specific learnings from Power One on DOS for Design that gave you confidence to restart the program?”
“It's my pleasure to introduce the president and CEO, Marcio Sousa, and the CFO, Tim Kelly of Praxis Precision Medicines. My name is Kevin Strang. I'm one of the biotech analysts at Goldman Sachs.”
“It's my pleasure to introduce the president and CEO, Marcio Sousa, and the CFO, Tim Kelly of Praxis Precision Medicines. My name is Kevin Strang. I'm one of the biotech analysts at Goldman Sachs.”
Affiliation history
-
Goldman Sachs
Analyst
Source not stated
Current